Chaperone “Discussed technology transfer with over 20 global pharmaceutical companies in Bio Europe””/>
ChaperoneIt was announced on the 11th that at ‘Bio Europe 2024‘, technology transfer discussions for core pipelines were held with about 20 global pharmaceutical companies. Starting with this event, technology transfer for Chaperone’s major pipeline is expected to gain further momentum.
Bio Europe 2024 is Europe’s largest bio conference attended by more than 2,800 pharmaceutical and bio companies and approximately 5,500 industry officials from over 60 countries around the world. This event was held in Stockholm, Sweden from the 4th to the 6th. At the conference, the latest trends and innovative technologies in the life sciences and bio-pharmaceutical industries were introduced, and various networking opportunities and partnering programs were provided.
At Bio Europe, Chaperone conducted active technology transfer discussions with global pharmaceutical companies on major pipelines such as atopic dermatitis treatment ‘Nugel’, Alzheimer’s treatment ‘Nucerin’, and nanobody-based dual antibody immunotherapy ‘Papiliximab’. Among these, technology transfer discussions regarding Nugel were the most active.
Nugel is the world’s first atopic dermatitis treatment with an inflammatory complex inhibition mechanism being developed by Chaperone. Nugel is currently undergoing phase 2b clinical trials in the United States. Part 1 administration is scheduled to be completed by the end of this year to confirm side effects and optimal dosage in multi-ethnic groups, including Caucasians. Starting next year, we plan to conduct Part 2 to confirm safety and effectiveness in various races based on the two confirmed optimal doses.
In this Bio Europe event, global pharmaceutical companies showed great interest in the results of Part 1 (dose expansion part) of the Nugel Phase 2b clinical trial being conducted in the United States. In particular, the company explained that the Part 1 trial confirmed the results of a dosage increase of up to 8 times the dosage used in domestic clinical trials, so inquiries about this and expectations about the results were high.
Chaperone introduced the research results and latest data on precision medicine-based biomarker technology that can predict treatment effects at Bio Europe and discussed technology transfer. Chaperone is taking a leading position in the field of precision medicine-based clinical trials by using blood biomarker technology to evaluate the efficacy of new drugs in advance.
For example, during the development of the Alzheimer’s drug Nucerin, the company is simultaneously developing diagnostic and therapeutic agents by applying biomarkers that can predict drug response and biomarkers for assessing drug response, which are essential for the development of dementia treatments. We are also developing companion diagnostic technology for atopic dermatitis treatment Nugel using precision medicine technology based on biomarkers for predicting drug response.
A Chaperone official said, “Many global pharmaceutical companies are expressing active interest to the extent that a follow-up meeting was held at this year’s Bio Europe following the last overseas conference.” He added, “In particular, while controlling the inflammatory response broadly, the side effects seen with immunomodulators so far have been minimized.” “We are particularly interested in Nugel’s differentiated technology and the Phase 2b clinical trial data being conducted in the U.S. on various races,” he said.
He continued, “Through this Bio Europe, we are working hard to ensure that technology transfer becomes visible after the U.S. phase 2b part 1 clinical trial data is released through active sales targeting candidates from global pharmaceutical companies capable of technology transfer.” He added, “Not only Nugel but also Nano. “Papiliximab, which uses a body-based bispecific antibody, is also highly regarded in the global market, so active technology transfer discussions are underway,” he added.
Reporter Kim Yu-rim youforest@hankyung.com
